Overview
This presentation will provide an update on how immunotherapy has rapidly integrated into standard 1st and 2nd-Line and beyond treatment settings. We will also review and discuss:
- the role of biomarker testing in clinical practice;
- management of toxicity associated with immunotherapy;
- immunotherapy treatment duration;
- newer combinations of therapies;
- and ongoing and planned pivotal trials.
After attending this program, participants will be able to:
- recognize ongoing and planned pivotal clinical trials of immunotherapy.
- identify patients eligible for clinical trial participation.
- specify immunotherapy for a select subset of patients likely to benefit.
David Spigel, MD
Chief Scientific Officer, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, Nashville, TN.
Program Chair: Ramaswamy Govindan, MD
Co-Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.
After attending this program, participants will be able to:
- recognize ongoing and planned pivotal clinical trials of immunotherapy.
- identify patients eligible for clinical trial participation.
- specify immunotherapy for a select subset of patients likely to benefit.
David Spigel, MD
Chief Scientific Officer, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, Nashville, TN.
Program Chair: Ramaswamy Govindan, MD
Co-Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.